IMDX — Insight Molecular Diagnostics Share Price
0.000.00%
Last trade - 00:00- $104.67m
- $74.57m
- $1.88m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 9.66 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 25.67 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -115.58% | ||
| Return on Equity | -534.37% | ||
| Operating Margin | -1524.15% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.22 | 2.2 | 0.96 | 1.5 | 1.88 | 3.04 | 4.4 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Insight Molecular Diagnostics Inc., formerly Oncocyte Corporation, is a molecular diagnostics technology company. The Company's technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is in the process of rebranding its VitaGraft assay (also known as VitaGraft Kidney), which is a lab developed test, under the name GraftAssureCore. The Company's transplant products include GraftAssureCore, GraftAssureDx, GraftAssureIQ. Its oncology products include DetermaCNI, DetermaIO, and OncoTIME. GraftAssureCore is a clinical blood-based solid organ transplantation monitoring test. GraftAssureIQ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. OncoTIME enables research on the tumor immune microenvironment.
Directors
- Cavan Redmond NEC (60)
- Ronald Andrews PRE (60)
- Mitchell Levine CFO
- Gisela Paulsen COO (55)
- Li Yu CAO
- Douglas Ross OTH
- Padma Sundar OTH
- Andrew Arno IND (61)
- Jennifer Carter IND (57)
- Melinda Griffith IND (66)
- Alfred Kingsley IND (78)
- Andrew Last IND (61)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- September 30th, 2009
- Public Since
- December 30th, 2015
- No. of Shareholders
- 182
- No. of Employees
- 46
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 28,599,285
- Address
- 2 International Plaza Dr. Suite 510, NASHVILLE, 37217
- Web
- https://imdxinc.com/
- Phone
- +1 6152558880
- Auditors
- Marcum LLP
Upcoming Events for IMDX
OncoCyte Corp Annual Shareholders Meeting
Q3 2025 OncoCyte Corp Earnings Release
Q3 2025 OncoCyte Corp Earnings Release
Similar to IMDX
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
What is the Insight Molecular Diagnostics share price?
As of Today at 18:02 UTC, shares in Insight Molecular Diagnostics are trading at $3.45. This share price information is delayed by 15 minutes.
How has the Insight Molecular Diagnostics share price performed this year?
Shares in Insight Molecular Diagnostics last closed at $3.45 and the price had moved by +30.19% over the past 365 days. In terms of relative price strength the Insight Molecular Diagnostics share price has outperformed the S&P500 Index by +16.88% over the past year.
What are the analyst and broker recommendations for Insight Molecular Diagnostics?
The overall consensus recommendation for Insight Molecular Diagnostics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Insight Molecular Diagnostics dividend yield?
Insight Molecular Diagnostics does not currently pay a dividend.
Does Insight Molecular Diagnostics pay a dividend?
Insight Molecular Diagnostics does not currently pay a dividend.
When does Insight Molecular Diagnostics next pay dividends?
Insight Molecular Diagnostics does not currently pay a dividend.
How do I buy Insight Molecular Diagnostics shares?
To buy shares in Insight Molecular Diagnostics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Insight Molecular Diagnostics?
As of the previous close price of $3.45, shares in Insight Molecular Diagnostics had a market capitalisation of $98.67m.
Where are Insight Molecular Diagnostics shares listed?
Here are the trading details for Insight Molecular Diagnostics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: IMDX
What kind of share is Insight Molecular Diagnostics?
Based on an overall assessment of its quality, value and momentum Insight Molecular Diagnostics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Insight Molecular Diagnostics share price forecast for 2025?
The analyst consensus target price for shares in Insight Molecular Diagnostics is $5.42. That is 57.1% above the last closing price of $3.45.
Analysts covering Insight Molecular Diagnostics currently have a consensus Earnings Per Share (EPS) forecast of -$0.95 for the next financial year.
Find out moreWhat is the trend in the Insight Molecular Diagnostics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Insight Molecular Diagnostics. Over the past six months, its share price has outperformed the S&P500 Index by +58.75%.
As of the last closing price of $3.45, shares in Insight Molecular Diagnostics were trading +21.94% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Insight Molecular Diagnostics PE Ratio?
The Insight Molecular Diagnostics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.45.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Insight Molecular Diagnostics?
Insight Molecular Diagnostics' management team is headed by:
- Cavan Redmond - NEC
- Ronald Andrews - PRE
- Mitchell Levine - CFO
- Gisela Paulsen - COO
- Li Yu - CAO
- Douglas Ross - OTH
- Padma Sundar - OTH
- Andrew Arno - IND
- Jennifer Carter - IND
- Melinda Griffith - IND
- Alfred Kingsley - IND
- Andrew Last - IND